Effect of 2,3-dihydro-1H-imidazo[1,2-b]pyrazole on the proliferation of mouse leukemic and normal cells in vivo

R. Ganapathi, A. Krishan

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Administration of 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY; NSC 51143), 250 to 500 mg/kg, in day 5 L1210 and P388 (ascites) tumor-bearing mice did not consistently prolong the life span of tumor-bearing animals. Flow cytometry and autoradiographic studies showed that, after 12 to 18 hr of a single IMPY injection, both P388 and L1210 tumor cells were synchronized in S phase. In contrast, IMPY inhibited cellular proliferation in both bone marrow and duodenal crypts during the first 24 hr, and a recovery was detectable only after 36 hr, returning to pretherapy values by 72 hr. Preliminary data indicate that this differential response of normal versus tumor cells to IMPY can be exploited to maximize chemotherapeutic efficacy in scheduled chemotherapy with cycle-specific agents.

Original languageEnglish
Pages (from-to)1103-1108
Number of pages6
JournalCancer Research
Volume40
Issue number4
StatePublished - Jan 1 1980
Externally publishedYes

Fingerprint

imidazopyrazole
Neoplasms
S Phase
Ascites
Flow Cytometry
Bone Marrow
Cell Proliferation
2,3-dihydro-1H-imidazo(1,2-b)pyrazole
Drug Therapy
Injections

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Effect of 2,3-dihydro-1H-imidazo[1,2-b]pyrazole on the proliferation of mouse leukemic and normal cells in vivo. / Ganapathi, R.; Krishan, A.

In: Cancer Research, Vol. 40, No. 4, 01.01.1980, p. 1103-1108.

Research output: Contribution to journalArticle

@article{2a67a0a479464e75a546f555cdb5504c,
title = "Effect of 2,3-dihydro-1H-imidazo[1,2-b]pyrazole on the proliferation of mouse leukemic and normal cells in vivo",
abstract = "Administration of 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY; NSC 51143), 250 to 500 mg/kg, in day 5 L1210 and P388 (ascites) tumor-bearing mice did not consistently prolong the life span of tumor-bearing animals. Flow cytometry and autoradiographic studies showed that, after 12 to 18 hr of a single IMPY injection, both P388 and L1210 tumor cells were synchronized in S phase. In contrast, IMPY inhibited cellular proliferation in both bone marrow and duodenal crypts during the first 24 hr, and a recovery was detectable only after 36 hr, returning to pretherapy values by 72 hr. Preliminary data indicate that this differential response of normal versus tumor cells to IMPY can be exploited to maximize chemotherapeutic efficacy in scheduled chemotherapy with cycle-specific agents.",
author = "R. Ganapathi and A. Krishan",
year = "1980",
month = "1",
day = "1",
language = "English",
volume = "40",
pages = "1103--1108",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Effect of 2,3-dihydro-1H-imidazo[1,2-b]pyrazole on the proliferation of mouse leukemic and normal cells in vivo

AU - Ganapathi, R.

AU - Krishan, A.

PY - 1980/1/1

Y1 - 1980/1/1

N2 - Administration of 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY; NSC 51143), 250 to 500 mg/kg, in day 5 L1210 and P388 (ascites) tumor-bearing mice did not consistently prolong the life span of tumor-bearing animals. Flow cytometry and autoradiographic studies showed that, after 12 to 18 hr of a single IMPY injection, both P388 and L1210 tumor cells were synchronized in S phase. In contrast, IMPY inhibited cellular proliferation in both bone marrow and duodenal crypts during the first 24 hr, and a recovery was detectable only after 36 hr, returning to pretherapy values by 72 hr. Preliminary data indicate that this differential response of normal versus tumor cells to IMPY can be exploited to maximize chemotherapeutic efficacy in scheduled chemotherapy with cycle-specific agents.

AB - Administration of 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY; NSC 51143), 250 to 500 mg/kg, in day 5 L1210 and P388 (ascites) tumor-bearing mice did not consistently prolong the life span of tumor-bearing animals. Flow cytometry and autoradiographic studies showed that, after 12 to 18 hr of a single IMPY injection, both P388 and L1210 tumor cells were synchronized in S phase. In contrast, IMPY inhibited cellular proliferation in both bone marrow and duodenal crypts during the first 24 hr, and a recovery was detectable only after 36 hr, returning to pretherapy values by 72 hr. Preliminary data indicate that this differential response of normal versus tumor cells to IMPY can be exploited to maximize chemotherapeutic efficacy in scheduled chemotherapy with cycle-specific agents.

UR - http://www.scopus.com/inward/record.url?scp=0018840869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018840869&partnerID=8YFLogxK

M3 - Article

C2 - 7357541

AN - SCOPUS:0018840869

VL - 40

SP - 1103

EP - 1108

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 4

ER -